In its 11 December 2018 press release, the Omeros Corporation announced a new collaboration with a UK university to create the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). Focus of the OC3IR will be research into OMS721 and OMS906, click HERE to read the corporate press release. “This partnership represents a tremendous opportunity to benefit from the renowned complement and inflammation expertise at Cambridge,” stated Gregory A. Demopulos, MD, chairman and CEO of Omeros whose press release remarks continue, “The result, we expect, will be good for Omeros, Cambridge and, most importantly, patients.”
Omeros’ drug development pipeline has been of interest within the aHUS arena for quite sometime, and has been mentioned in aHUS Alliance pharma overviews to include most recently our May 2018 aHUS Therapeutic Drug Pipeline edition. Atypical HUS is a very rare disease, affecting an estimated 2 people per million, with diagnosis made difficult by having common symptoms similar to other forms of thrombotic microangiopathy. This innovative center at Cambridge is not only a new opportunity for scientific and drug discovery stakeholders, but OC3IR brings an expanded horizon of pathways to engage in dialogue. It also broadens the depth and scope of people at Omeros and the University of Cambridge involved with the new center, causing aHUS advocates to ponder the following questions (which are not listed in any particular order).
Physicians, research teams, and aHUS patients and their families are looking forward to seeing how the Omeros Center at Cambridge for Complement and Inflammation Research plans to create better patient outcomes for those challenged aHUS and other diseases.
More on Atypical HUS
aHUS Press Kit – Fact Sheets, Graphics, White Papers, aHUS Awareness Day (24 Sept campaigns) & More
Omeros – Links & Info
Omeros Corp: 1 Oct 2018 (press release)
“Omeros also has identified MASP-3 as responsible for the conversion of pro-factor D to factor D and as a critical activator of the human complement system’s alternative pathway”
“Phase 3 clinical programs are in progress forOMS721 in atypical hemolytic uremic syndrome (aHUS), in immunoglobulin A (IgA) nephropathy and in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).”
Information from Omeros Corp. regarding OMS906 – Click HERE
Of the 327 clinical trials for thrombotic microangiopathy, here are a few on this topic:
NCT03205995: Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT02222545: Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
NCT02355782: OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy
From Omeros Pharmaceutical’s corporate website, Investors
Click HERE and scroll down to ‘Featured Presentations’ to view the fullpresentation. (Next-Generation Therapeutics TransformingPatient Care Today, presented by Gregory A. Demopulos MD, Omeros Corp. Chairman & CEO)
Presentation Slide #3: Omeros Pipeline
Presentation Slide #23: OMS721, Summary of aHUS Program
Presentation Slide #11: OMS721, MASP-2 vs C5 inhibitor